GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Quick Ratio

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Quick Ratio : 1.76 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Coeptis Therapeutics Holdings's quick ratio for the quarter that ended in Dec. 2023 was 1.76.

Coeptis Therapeutics Holdings has a quick ratio of 1.76. It generally indicates good short-term financial strength.

The historical rank and industry rank for Coeptis Therapeutics Holdings's Quick Ratio or its related term are showing as below:

COEP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04   Med: 1.28   Max: 1.81
Current: 1.76

During the past 4 years, Coeptis Therapeutics Holdings's highest Quick Ratio was 1.81. The lowest was 0.04. And the median was 1.28.

COEP's Quick Ratio is ranked worse than
67.68% of 1553 companies
in the Biotechnology industry
Industry Median: 3.49 vs COEP: 1.76

Coeptis Therapeutics Holdings Quick Ratio Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Quick Ratio Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Quick Ratio
0.04 0.79 1.81 1.76

Coeptis Therapeutics Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.81 1.15 1.37 2.55 1.76

Competitive Comparison of Coeptis Therapeutics Holdings's Quick Ratio

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coeptis Therapeutics Holdings's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's Quick Ratio falls into.



Coeptis Therapeutics Holdings Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Coeptis Therapeutics Holdings's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(5.25-0)/2.989
=1.76

Coeptis Therapeutics Holdings's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(5.25-0)/2.989
=1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coeptis Therapeutics Holdings  (NAS:COEP) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Coeptis Therapeutics Holdings Quick Ratio Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Executives
Tara Desilva director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick director, 10 percent owner, officer: CEO and President 5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind director 1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace director, officer: VP of Operations 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise director, 10 percent owner, officer: Chief Financial Officer 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps director 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy officer: CFO and Secretary 206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc 10 percent owner 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr. 10 percent owner 151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp 10 percent owner 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019